NBTXR3

0:01:27

Mode of action: NBTXR3

0:07:25

Phase 1 results of NBTXR3 treatment for locally advanced HNSCC in elderly patients

0:18:48

R&D Day 2018 - Immuno-Oncology and NBTXR3: What lies Ahead

0:24:25

R&D Day 2018 - NBTXR3 in the US: The 1100 Trial

0:07:52

Multidisciplinary Head and Neck Symposium - NBTXR3 Intratumoral Injection

0:09:50

1/4) How NBTXR3 Works and its Local and Systemic Responses – Sebastien Paris, PhD

0:16:09

3/4) NBTXR3 in R/M HNSCC, the 1100 Study – Colette Shen, MD PhD

0:32:53

4/4) Panel session: the Role of NBTXR3 and Immune Oncology in Advancing Head&Neck Cancer | 05.18.24

0:09:42

Multidisciplinary Head and Neck Symposium - NBTXR3

0:08:12

First-in-human trial of intratumoral injection of SYNB1891

0:05:37

Nanobiotix approval for liver cancer trials

0:18:13

R&D Day 2018 - Laurent Levy CEO & Founder

0:04:11

Nanobiotix hopes for early launch of cancer treatment

0:05:30

Immuno-oncology a “logical step” for Nanobiotix, says chief

0:21:53

Fireside Chat with Laurent Levy, Co-Founder & CEO, Nanobiotix Corp.

1:32:04

Virtual KOL Discussion of New Immunotherapy Data presented at ASCO 2021

0:14:08

2/4) Challenges and Opportunities in Recurrent/Metastatic Head and Neck Cancer - Ari Rosenberg, MD

0:09:04

Dr. Weiss on Enhancing Tumor Control With JNJ-1900

0:10:42

Laurent Levy Président du Directoire Nanobiotix : “Nous pensons que le plus dur est fait” : #Biot...

0:00:56

Nanobiotix - Sebastian Freund GMA Lead @ 4TH CLINICAL TRIALS NEXUS MUNICH GERMANY OCT 2019

0:17:49

R&D Day - Local Control for Head & Neck Cancer

0:01:56

[C4RT] Autonomous Robotics Solution that Empowers Labor Intensive Industry

1:02:51

Study 1100 Phase I Results Webinar

0:01:45

Intratumoral immunotherapy with aluminum hydroxide-tethered IL-12